MCID: EST002
MIFTS: 41

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to breast cancer and bartholin's gland benign neoplasm. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Endometrial cancer and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Letrozole and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 breast cancer 11.0
2 bartholin's gland benign neoplasm 10.8 ESR1 PGR
3 central nervous system organ benign neoplasm 10.8 ESR1 PGR
4 gallbladder leiomyoma 10.8 ESR1 PGR
5 lung adenoma 10.8 ESR1 PGR
6 gastritis 10.8 ERBB2 PGR
7 nerve fibre bundle defect 10.8 ERBB2 ESR1
8 fallopian tube benign neoplasm 10.8 ESR1 PGR
9 paranasal sinus disease 10.8 ESR1 PGR
10 dartoic leiomyoma 10.8 ESR1 PGR
11 ulceroglandular tularemia 10.8 AR ESR1
12 urinary bladder inverted papilloma 10.8 ESR1 PGR
13 deafness, autosomal dominant 8/12 10.7 ESR1 PGR
14 skin sarcoma 10.7 ERBB2 PGR
15 her2-receptor negative breast cancer 10.7 ERBB2 PGR
16 intestinal perforation 10.7 ESR1 PGR
17 superficial basal cell carcinoma 10.7 ESR1 PGR
18 vitamin d-dependent rickets type ii 10.7 AR ESR1
19 pineal region meningioma 10.7 ESR1 PGR
20 bladder colloid adenocarcinoma 10.7 ESR1 PGR
21 ovarian mesodermal adenosarcoma 10.7 ESR1 PGR
22 fibrogenesis imperfecta ossium 10.7 EGF ERBB2
23 endophthalmitis 10.7 ESR1 PGR
24 benign fibrous mesothelioma 10.7 EGF ESR1
25 chest wall lymphoma 10.7 ESR1 PGR
26 brenner tumor of the vagina 10.7 ERBB2 ESR1
27 kallmann syndrome 10.7 ERBB2 PGR
28 colon neuroendocrine neoplasm 10.7 ERBB2 PGR
29 bowman's membrane folds or rupture 10.7 AR PGR
30 cutaneous mucoepidermoid carcinoma 10.7 ESR1 PGR
31 penis squamous cell carcinoma 10.7 ERBB2 PGR
32 retinal detachment 10.7 ESR1 PGR
33 brenner tumor of ovary 10.7 ERBB2 ESR1
34 x-linked intellectual disability, porteous type 10.6 EGF ERBB2
35 holoprosencephaly 6 10.6 ESR1 PGR
36 acute thyroiditis 10.6 ESR1 PGR
37 retinitis pigmentosa 20 10.6 ESR1 PGR
38 breast fibrosarcoma 10.6 ERBB2 PGR
39 pemphigus vulgaris, familial 10.6 AR ERBB2
40 urethra clear cell adenocarcinoma 10.6 ESR1 PGR
41 breast sarcoma 10.6 ERBB2 ESR1
42 glaucoma, hereditary 10.6 ERBB2 ESR1 PGR
43 spinal cancer 10.6 ERBB2 ESR1 PGR
44 subglottis verrucous carcinoma 10.6 ERBB2 ESR1 PGR
45 her2-receptor positive breast cancer 10.6 ERBB2 ESR1 PGR
46 otitis externa 10.5 ERBB2 PGR
47 rectal neoplasm 10.5 ESR1 PGR
48 organ system benign neoplasm 10.5 ERBB2 ESR1 PGR
49 cartilage cancer 10.5 ERBB2 ESR1 PGR
50 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.5 ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.92 EGF ERBB2 ESR1 ETS1 FOXA1 PGR
2 growth/size/body region MP:0005378 9.91 ERBB2 ESR1 ETS1 FOXA1 PTPRA WNT5A
3 digestive/alimentary MP:0005381 9.85 AR EGF ERBB2 ESR1 FOXA1 WNT5A
4 immune system MP:0005387 9.76 AR CCAR2 EGF ESR1 ETS1 FOXA1
5 integument MP:0010771 9.5 AR EGF ERBB2 ESR1 ETS1 FOXA1
6 neoplasm MP:0002006 9.1 AR CCAR2 ERBB2 ESR1 FOXA1 PGR

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
2
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
6
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
7
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Fluorouracil Approved Phase 4,Phase 3,Phase 2 51-21-8 3385
10
Lenograstim Approved Phase 4,Phase 3,Phase 2 135968-09-1
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
13
Pamidronate Approved Phase 4 40391-99-9 4674
14
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
16
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
17
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
18
Pertuzumab Approved Phase 4,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
19
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
20
Fosaprepitant Approved Phase 4 172673-20-0 219090
21
Ondansetron Approved Phase 4 99614-02-5 4595
22
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
23
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
24
Substance P Investigational Phase 4 33507-63-0 44359816
25 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
45 Diphosphonates Phase 4,Phase 3
46 Antiemetics Phase 4,Phase 2
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Autonomic Agents Phase 4,Phase 2
49 BB 1101 Phase 4,Phase 2
50 Dermatologic Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 605)

id Name Status NCT ID Phase Drugs
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
3 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
4 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4 Letrozole
5 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
6 Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Completed NCT00237133 Phase 4 Letrozole
7 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4 Toremifene; Anastrozole
8 Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer Recruiting NCT02549677 Phase 4 Epirubicin;Docetaxel;cyclophosphamide
9 Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients Recruiting NCT02062489 Phase 4 Tamoxifen;Placebo
10 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Recruiting NCT01176916 Phase 4 Aromasin (exemestane)
11 Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Active, not recruiting NCT01913990 Phase 4 Dexamethasone, Ondansetron, Aprepitant
12 MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Active, not recruiting NCT01501487 Phase 4 TAC chemotherapy;TC chemotherapy;Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy;TCH chemotherapy;T + trastuzumab followed by CEF + trastuzumab;Dose dense AC followed by T + trastuzumab;Dose dense AC followed by T + trastuzumab + pertuzumab;PTH followed by dose dense AC of FEC
13 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Not yet recruiting NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
14 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Terminated NCT00375752 Phase 4 Letrozole;Zolendronic Acid
15 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
16 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
17 Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery Unknown status NCT00039546 Phase 3 cyclophosphamide;epirubicin hydrochloride;gemcitabine hydrochloride;paclitaxel
18 Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Unknown status NCT00253422 Phase 3 anastrozole;exemestane;fulvestrant
19 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel 125 mg/m2;Carboplatin AUC 2;gemcitabine 1000 mg
20 A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer Completed NCT00938652 Phase 3 gemcitabine/carboplatin;Iniparib
21 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
22 Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer Completed NCT01986569 Phase 3 [18F]fluoroestradiol (FES)
23 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
24 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
25 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
26 Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer Completed NCT01712893 Phase 3 Zoladex
27 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed NCT01300351 Phase 3 Fulvestrant;Placebo
28 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
29 Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes Completed NCT00966043 Phase 3
30 Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers Completed NCT00535418 Phase 2, Phase 3 Letrozole
31 Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Completed NCT00130533 Phase 3 Capecitabine
32 PROACT - Pre-Operative Arimidex Compared To Tamoxifen Completed NCT00232661 Phase 3 ARIMIDEX (anastrazole);NOLVADEX (tamoxifen)
33 Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Completed NCT00944918 Phase 3 fulvestrant;anastrozole;exemestane
34 Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer Completed NCT00352378 Phase 3 Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
35 A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer Completed NCT00022672 Phase 3 trastuzumab (Herceptin®);anastrazole (Arimidex®)
36 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients Completed NCT01099436 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;zoledronic acid
37 Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Completed NCT00567554 Phase 3 epirubicin - cyclophosphamide / docetaxel;epirubicin - cyclophosphamide / docetaxel + bevacizumab;paclitaxel;paclitaxel + everolimus (RAD001);epirubicin - cyclophosphamide / docetaxel + trastuzumab;epirubicin - cyclophosphamide / docetaxel + lapatinib
38 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed NCT00863655 Phase 3 Everolimus;Exemestane;Everolimus Placebo
39 Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment Completed NCT00605267 Phase 3 Tamoxifen;Anastrazole (Arimidex);Goserelin acetate (Zoladex)
40 Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer Completed NCT00002967 Phase 3 cyclophosphamide;doxorubicin hydrochloride;octreotide pamoate;tamoxifen citrate
41 Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. Completed NCT00314977 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel
42 Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy Recruiting NCT01805271 Phase 3 Everolimus;Placebo
43 Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer Recruiting NCT02535221 Phase 3 Goserelin+TAM+AI;Epirubicin+CTX+5-Fu
44 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
45 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Recruiting NCT02297438 Phase 3 Palbociclib;Letrozole;Placebo;Letrozole
46 Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment Recruiting NCT01564056 Phase 3 HORMONOTHERAPY;CHEMOTHERAPY then HORMONOTHERAPY
47 PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Recruiting NCT03079011 Phase 3 Palbociclib 125mg;Aromatase Inhibitors;Fulvestrant Injectable Product
48 Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT Recruiting NCT02376985 Phase 3 Everolimus
49 A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy Recruiting NCT02340221 Phase 3 Taselisib;Placebo;Fulvestrant
50 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

39
Breast, Lymph Node, Bone, Testes, Brain, Lung, T Cells

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 176)
id Title Authors Year
1
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. ( 28238761 )
2017
2
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )
2017
3
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )
2017
4
WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. ( 28469783 )
2017
5
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. ( 28881566 )
2017
6
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. ( 28877935 )
2017
7
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. ( 28280355 )
2017
8
The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )
2016
9
Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )
2016
10
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )
2016
11
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )
2016
12
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )
2016
13
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )
2016
14
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". ( 26874356 )
2016
15
Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )
2016
16
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )
2016
17
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )
2016
18
Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )
2016
19
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )
2016
20
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. ( 25852060 )
2015
21
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )
2015
22
Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )
2015
23
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )
2015
24
Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )
2015
25
NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )
2015
26
Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )
2015
27
Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )
2015
28
Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )
2015
29
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )
2015
30
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )
2015
31
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )
2015
32
Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )
2015
33
Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. ( 25081341 )
2014
34
Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )
2014
35
The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. ( 25275589 )
2014
36
Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )
2014
37
Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. ( 24850180 )
2014
38
Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )
2014
39
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )
2014
40
A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )
2014
41
In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )
2014
42
The prevalence of estrogen receptor-negative breast cancer in Ethiopia. ( 25433805 )
2014
43
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )
2014
44
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )
2014
45
Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer? ( 23325583 )
2013
46
Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells. ( 24649031 )
2013
47
High expression of class III I^-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. ( 23218766 )
2013
48
Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. ( 23840429 )
2013
49
Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. ( 23533663 )
2013
50
Antineoplastic effects of I+-santalol on estrogen receptor-positive and estrogen receptor-negative breast cancer cells through cell cycle arrest at G2/M phase and induction of apoptosis. ( 23451128 )
2013

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.8 EGF ERBB2 PTPRA

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.93 AR ESR1 ETS1 FOXA1 PGR WNT5A
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 AR EGF ESR1 ETS1 WNT5A
3 regulation of transcription from RNA polymerase II promoter GO:0006357 9.83 AR ERBB2 ESR1 ETS1 FOXA1
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR ESR1 PGR
5 positive regulation of angiogenesis GO:0045766 9.74 CXCL8 ETS1 WNT5A
6 male gonad development GO:0008584 9.72 AR ESR1 WNT5A
7 response to estradiol GO:0032355 9.71 ESR1 ETS1 FOXA1
8 regulation of cell motility GO:2000145 9.61 EGF ERBB2
9 positive regulation of phosphorylation GO:0042327 9.6 AR EGF
10 dopaminergic neuron differentiation GO:0071542 9.58 FOXA1 WNT5A
11 uterus development GO:0060065 9.58 ESR1 WNT5A
12 negative regulation of ERBB signaling pathway GO:1901185 9.56 EGF ERBB2
13 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.52 AR ERBB2
14 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.51 AR FOXA1
15 steroid hormone mediated signaling pathway GO:0043401 9.5 AR ESR1 PGR
16 vagina development GO:0060068 9.49 ESR1 WNT5A
17 prostate gland epithelium morphogenesis GO:0060740 9.4 AR FOXA1
18 positive regulation of cell-cell adhesion mediated by cadherin GO:2000049 9.37 FOXA1 WNT5A
19 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.26 ESR1 WNT5A
20 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.16 AR PGR
21 lateral sprouting involved in mammary gland duct morphogenesis GO:0060599 8.96 AR WNT5A
22 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1
23 transcription, DNA-templated GO:0006351 10.16 AR CCAR2 ERBB2 ESR1 ETS1 FOXA1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 AR CCAR2 ESR1 PGR
2 sequence-specific DNA binding GO:0043565 9.8 AR ESR1 ETS1 FOXA1 PGR
3 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 AR ESR1 ETS1 FOXA1 PGR WNT5A
4 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.78 AR ESR1 ETS1 PGR
5 transcription factor binding GO:0008134 9.73 AR ESR1 ETS1 FOXA1
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 EGF ERBB2 PTPRA
7 ATPase binding GO:0051117 9.54 AR ESR1 PGR
8 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
9 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.33 AR ESR1 PGR
10 steroid binding GO:0005496 9.13 AR ESR1 PGR
11 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.02 AR ESR1 ETS1 FOXA1 PGR

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....